ATOS Reports $0 Revenue, -$0.08 EPS, FDA Rare Pediatric & Orphan Designations for (Z)-Endoxifen in DMD, 2025 Clinical Trials Arena Award
Atossa Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $5.11
-5.7% since the alert
$5.42 → $5.11
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS